Analysts Are Bullish on These Healthcare Stocks: Quoin Pharmaceuticals (QNRX), Biodesix (BDSX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Quoin Pharmaceuticals (QNRX – Research Report), Biodesix (BDSX – Research Report) and BioCryst (BCRX – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Quoin Pharmaceuticals (QNRX)
In a report issued on February 25, Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals, with a price target of $70.00. The company’s shares closed last Friday at $8.56.
According to TipRanks.com, Rahman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Quoin Pharmaceuticals is a Moderate Buy with an average price target of $70.00.
See Insiders’ Hot Stocks on TipRanks >>
Biodesix (BDSX)
In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Biodesix. The company’s shares closed last Friday at $15.19.
According to TipRanks.com, Bonello is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biodesix with a $30.00 average price target, a 102.8% upside from current levels. In a report released today, William Blair also upgraded the stock to Buy.
BioCryst (BCRX)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on BioCryst today and set a price target of $32.00. The company’s shares closed last Friday at $8.78, close to its 52-week high of $9.50.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $21.50, representing a 170.4% upside. In a report issued on February 18, Evercore ISI also resumed coverage with a Buy rating on the stock with a $17.00 price target.
